Perspecive
Volume 17:01, 2025

Journal of Bioanalysis & Biomedicine

ISSN: 1948-593X

Open Access

Validation of HPLC-Based Assays for Therapeutic Drug Monitoring Applications

Ewa Kowalczyk*

Department of Physics, University of Toyama, 3190 Gofuku, Toyama, 930-8555, Japan

Introduction

Therapeutic Drug Monitoring (TDM) is an essential clinical practice used to optimize drug efficacy and minimize toxicity by measuring specific drug concentrations in a patient's blood at designated intervals. This is especially critical for drugs with narrow therapeutic windows, significant inter-individual variability in pharmacokinetics, or a strong relationship between plasma concentration and clinical response. High-Performance Liquid Chromatography (HPLC) has become one of the most widely employed analytical techniques for TDM due to its precision, sensitivity, and versatility. However, before an HPLC-based assay can be utilized in routine clinical practice, it must undergo rigorous validation to ensure its reliability, reproducibility, and regulatory compliance. Method validation serves as the cornerstone for laboratory accreditation and patient safety, confirming that the assay performs consistently under specified conditions for its intended purpose [1].

Description

Validation of an HPLC-based assay for TDM involves a comprehensive assessment of several critical performance parameters in accordance with guidelines from regulatory agencies such as the FDA, EMA, and ICH. These parameters include specificity, linearity, accuracy, precision, limit of detection (LOD), limit of quantitation (LOQ), robustness, and stability. Specificity evaluates the assay's ability to differentiate the target analyte from endogenous compounds, metabolites, or other co-administered drugs that might interfere with detection. This is crucial in TDM, where multiple medications may be present in a patient's biological matrix. Linearity refers to the assay's ability to provide results directly proportional to the concentration of the analyte across a specified range, typically determined using calibration curves with at least five concentration points.

Accuracy and precision are perhaps the most critical parameters, reflecting the assay's ability to yield correct and consistent results. Accuracy is assessed by comparing the measured concentration to a known reference, while precision evaluates repeatability (intra-day variation) and intermediate precision (inter-day variation). Both should fall within ±15% for bioanalytical assays, according to FDA guidance. LOD and LOQ define the smallest amount of drug that can be reliably detected and quantified, respectively. These are essential for drugs with very low plasma concentrations or for early-phase pharmacokinetic studies. Furthermore, robustness assesses the assay's resilience to slight procedural variations, such as changes in flow rate or column temperature, ensuring stability across different lab environments or equipment.

Sample preparation is another critical aspect of HPLC method validation for TDM. Biological samples such as plasma, serum, or whole blood often require protein precipitation, solid-phase extraction (SPE), or liquid-liquid extraction (LLE) to isolate the analyte and reduce matrix effects. The efficiency and reproducibility of these steps are tested during validation to ensure the overall method's reliability. Stability testing, including short-term, long-term, freeze-thaw, and autosampler stability, ensures that drug concentrations remain unchanged during sample storage and analysis. These assessments are especially important for clinical laboratories that may need to batch process samples or transport them between facilities [2].

Conclusion

The validation of HPLC-based assays for therapeutic drug monitoring is a meticulous, multi-faceted process that ensures analytical reliability, clinical relevance, and regulatory adherence. With growing demand for personalized medicine and precision pharmacotherapy, the role of validated HPLC methods in TDM continues to expand. By confirming parameters such as specificity, accuracy, precision, and stability, method validation not only supports laboratory accreditation and quality assurance but also directly impacts patient care through reliable dose adjustment and monitoring. As technology advances and newer detection systems like LC-MS/MS complement HPLC, robust validation protocols will remain vital in translating analytical performance into therapeutic confidence. Ultimately, validated HPLC methods contribute significantly to safer and more effective clinical decision-making in pharmacotherapy.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Wang, Zhenzhen, Zhu, Jiaqi, Gu, Hong, et al. "The clinical significance of abnormal Tim-3 expression on NK cells from patients with gastric cancer." *Immunol Investig* 44 (2015): 578–589.

2. Wakiyama, Hiroshi, Masuda, Takashi, Motomura, Yuki, et al. "Cytolytic activity (CYT) score is a prognostic biomarker reflecting host immune status in hepatocellular carcinoma (HCC)." *Anticancer Res* 38 (2018): 6631–6638.

***Address for Correspondence:** Ewa Kowalczyk, Department of Physics, University of Toyama, 3190 Gofuku, Toyama, 930-8555, Japan; E-mail: ewa@kowalczyk.jp*

Received: 01 February, 2025, Manuscript No. jbabm-25-168526; **Editor Assigned:** 03 February, 2025, PreQC No. P-168526; **Reviewed:** 17 February, 2025, QC No. Q-168526; **Revised:** 22 February, 2025, Manuscript No. R-168526; **Published:** 28 February, 2025, DOI: 10.37421/1948-593X.2025.17.479

How to cite this article: Kowalczyk, Ewa. "Validation of HPLC-Based Assays for Therapeutic Drug Monitoring Applications." J Bioanal Biomed 17 (2025): 479.